Abstract
Background. Management with genetically engineered biologic drugs is recommended for patients with palmoplantar psoriasis when standard external therapy, physical therapy, and classical immunosuppressants lack efficacy. We present the results of ustekinumab administration in children with palmoplantar psoriasis resistant to standard therapy. Clinical case description. The results of ustekinumab administration in 12 children with palmoplantar psoriasis are presented. No comorbid pathologies were revealed in these patients during further examination. Thus, genetically engineered biologic therapy with ustekinumab (45 mg subcutaneously according to the recommended treatment regimen) was initiated due to the absence of any contraindications. 58.33% of all patients have achieved lower scores of PASI 90 index 12 weeks after therapy initiation. Conclusion. Management with genetically engineered biologic drugs such as ustekinumab (according to recommended regimen) may be suggested for patients with palmoplantar psoriasis due to its systemic chronic pathological process and lesions of functionally significant areas and in cases when standard external therapy, physical therapy, and classical immunosuppressants lack efficacy, in the absence of contraindications.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
